NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Global Atopic Dermatitis Market - 2019-2026

出版商 DataM Intelligence 商品編碼 792793
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
異位性皮膚炎的全球市場 Global Atopic Dermatitis Market - 2019-2026
出版日期: 按訂單生產內容資訊: 英文


第1章 調查手法·範圍

第2章 全球異位性皮膚炎市場:主要趨勢與發展

  • 主要趨勢與發展

第3章 全球異位性皮膚炎市場:產業分析

  • 促進因素
  • 阻礙因素
  • 威脅和機會
  • 波特的五力分析

第4章 全球異位性皮膚炎市場:市場分析

  • 疾病重症度別
    • 輕度
    • 中度
    • 重度
  • 治療類別
    • 皮質類固醇
    • 抗組織胺藥
    • Calcineurin抑制劑
    • 免疫調節劑
    • 生物學的療法
    • PDE-4抑制劑
    • 抗生素
    • 保濕劑/皮膚軟化劑
    • 非適應症療法
  • 各流通管道
    • 醫院
    • 皮膚科診所
    • 零售藥局
    • 線上藥局

第5章 全球異位性皮膚炎市場:地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

第6章 全球異位性皮膚炎市場:競爭情形

  • 市場佔有率分析
  • M&A分析
  • 新產品銷售

第7章 企業簡介

  • LEO Pharma
  • Mylan
  • Novartis
  • Pfizer, Inc
  • Sanofi
  • Valeant

第8章 附錄


Atopic Dermatitis is a chronic inflammatory disease of the skin and is highly prevalent in children with ~85% of cases present by 5 years of age. It is characterized by flare ups of itch, red inflamed rash and excessive dryness or scaling of skin. Globally, AD affects 15-20% of children and 1-3% of adults. The global AD market size is estimated at USD 4.8 billion, growing at an annual growth rate of 4% over the forecast period.

The large and growing patient population with atopic dermatitis and eczema represents an attractive revenue potential for companies. Some of the major growth drivers for the market include launch of biologics for the treatment of moderate to severe disease, increase in uptake of topical calcineurin inhibitors within the emerging markets, and continued uptake of systemic therapies. However, high cost of biologic therapy, uptake of generic topical drugs and pediatric population being the largest patient segment will act as deterrent to market growth.

A significant shift in treatment paradigm for AD is expected over the next few years with the launch of biologics and novel small molecules. Novel therapies are likely to generate high demand from patients with moderate to severe atopic dermatitis, since an estimated 19% of patients do not respond to currently available treatment regimens. Novel therapeutic target: dupilumab is touted as a potential breakthrough therapy for moderate to severe disease. It approved by the Food and Drug Administration (FDA) in March 2017 and is estimated to achieve peak annual sales of USD 4 billion.

The global Atopic Dermatitis market report segments the market by disease severity, by treatment type, by mode of administration, by distribution channel, and lastly by region. Based on different clinical signs and intensity of symptoms, the AD market is classified into three types - mild, moderate, and severe. This categorization helps healthcare provider to determine best course of treatment. Segmentation based on treatment types used includes drug classes such as corticosteroids, antihistamines, calcineurin inhibitors, Immunomodulators, biologic therapy, PDE-4 inhibitor, antibiotics, moisturizers/emollients, and Off-label therapies. Topical corticosteroids are the most widely used pharmacologic treatment for AD and often recommended as first-line therapy for moderate-severe disease. Next is calcineurin inhibitors that is used as second-line treatment and is the only non-steroidal pharmacologic therapy approved for atopic dermatitis. Lastly, the market is classified based on distribution channel into Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy.

Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific and RoW. North America is the largest market for Atopic Dermatitis owing to a large and growing patient population with atopic dermatitis and eczema. Around 17.8 million people in the have some form of atopic dermatitis. Thus, the US represents a huge target market for AD. The US atopic dermatitis market is valued at USD 1.7 billion, growing at an annual rate of 4%.

The report also profiles the following companies in the atopic dermatitis market - Pfizer Inc., Mylan N.V, LEO Pharma Inc., Novartis, Sanofi, and Valeant. Anacor, a biotech company making non-steroidal topical PDE4 inhibitor crisaborole, was acquired by Pfizer in 2016.

Scope of the Report:

By Disease Severity

  • Mild
  • Moderate
  • Severe

By Treatment Type

  • Corticosteroids
  • Antihistamines
  • Calcineurin Inhibitors
  • Immunomodulators
  • Biologic Therapy
  • PDE-4 Inhibitor
  • Antibiotics
  • Moisturizers/Emollients
  • Off-Label Therapies

By Distribution Channel

  • Hospitals
  • Dermatology Clinics
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
  • North America (The USA, Canada, Mexico)
  • South America (Brazil, Argentina, Rest of South America)
  • Rest of the World

Why purchase the report?

  • Visualize the composition of the Atopic Dermatitis market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
  • Identify commercial opportunities in Atopic Dermatitis market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the Atopic Dermatitis market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key Atopic Dermatitis of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Scope of the Report

Chapter 2 Global Atopic Dermatitis Market - Trends

  • 2.1 Key Trends & Developments

Chapter 3 Global Atopic Dermatitis Market - Industry Analysis

  • 3.1 Market Drivers
    • 3.1.1. Large patient population of eczema
    • 3.1.2. Approval of biologics and novel molecules
  • 3.2 Market Restraints
    • 3.2.1. High cost of biologic therapy
    • 3.2.2. Pediatric population being the largest patient segment
  • 3.3 Threats and Opportunities
  • 3.2 Porter's 5 Forces

Chapter 4 Global Atopic Dermatitis Market - Market Analysis

  • 4.1. Atopic Dermatitis Market - By Disease Severity
    • 4.1.1 Mild
    • 4.1.2 Moderate
    • 4.1.3 Severe
  • 4.2 Atopic Dermatitis Market- By Treatment Type
    • 4.2.1. Corticosteroids
    • 4.2.2. Antihistamines
    • 4.2.3. Calcineurin Inhibitors
    • 4.2.4. Immunomodulators
    • 4.2.5. Biologic Therapy
    • 4.2.6. PDE-4 Inhibitor
    • 4.2.7. Antibiotics
    • 4.2.8. Moisturizers/Emollients
    • 4.2.9. Off-Label Therapies
  • 4.3 Atopic Dermatitis Market- By Distribution Channel
    • 4.3.1 Hospitals
    • 4.3.2 Dermatology Clinics
    • 4.3.3 Retail Pharmacy
    • 4.3.4 Online Pharmacy

Chapter 5 Global Atopic Dermatitis Market - Geographical Analysis

  • 5.1. North America
    • 5.1.1. The USA
    • 5.1.2. Canada
    • 5.1.3. Mexico
  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. The UK
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. Rest of Europe
  • 5.3. Asia Pacific
    • 5.3.1. China
    • 5.3.2. Japan
    • 5.3.3. India
    • 5.3.4. Australia
    • 5.3.5. Rest of Asia Pacific
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5 Rest of the World

Chapter 6 Global Atopic Dermatitis Market - Competitive Landscape

  • 6.1. Market Share Analysis
  • 6.2. Mergers and Acquisitions Analysis
  • 6.3. New Product Launches

Chapter 7 Global Atopic Dermatitis Market - Company Profiles

  • 1.1. LEO Pharma
  • 1.2. Mylan
  • 1.3. Novartis
  • 1.4. Pfizer, Inc
  • 1.5. Sanofi
  • 1.6. Valeant

Chapter 8 Global Atopic Dermatitis Market - Appendix

  • 8.1 Sources
  • 8.2 List of Tables